Hillhurst Biopharmaceuticals

Executive Summary

Hillhurst Biopharmaceuticals is a private biotech company leveraging its proprietary GLASS (Gas in Liquid Advanced Stability System) platform to enable oral delivery of therapeutic gases and volatile agents that were previously limited to inhaled administration. Founded in 2018 and headquartered in San Diego, the company aims to improve dosing accuracy, efficacy, safety, and patient convenience, particularly for at-home use. Hillhurst is currently in Phase 2 development, focusing on small molecule therapies delivered via its novel oral formulation technology. The platform has the potential to transform the treatment landscape for conditions requiring precise gas-based therapeutics, such as pulmonary or cardiovascular diseases. While the company has not disclosed specific financials or valuation, its innovative approach addresses a significant unmet need in drug delivery, positioning it for potential partnerships or licensing deals with larger pharmaceutical firms.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 Clinical Data Readout60% success
• Q4 2026Strategic Partnership or Licensing Agreement50% success
• Q2 2026Series B or Series C Financing Round70% success